Inferior Vena Cava Filters (IVCF) Pipeline Report 2024: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Inferior Vena Cava Filters (IVCF) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" report has been added to * ResearchAndMarkets.com's* offering.
This report provides comprehensive information about the Inferior Vena Cava Filters (IVCF) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Inferior Vena Cava Filter (IVCF) is a metallic device used to prevent blood clots from traveling to lungs. The filter is inserted inside a large vein called the inferior vena cava (which carries blood from lower extremities to the heart). IVC filter traps blood clots before it reaches to the lungs.
*Scope*
· Extensive coverage of the Inferior Vena Cava Filters (IVCF) under development
· The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
· The report reviews the major players involved in the development of Inferior Vena Cava Filters (IVCF) and list all their pipeline projects
· The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
· The report provides key clinical trial data of ongoing trials specific to pipeline products
· Recent developments in the segment / industry
*Reasons to Buy*
· Formulate significant competitor information, analysis, and insights to improve R&D strategies
· Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
· Identify and understand important and diverse types of Inferior Vena Cava Filters (IVCF) under development
· Develop market-entry and market expansion strategies
· Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
· In-depth analysis of the product's current stage of development, territory and estimated launch date
*Key Topics Covered:*
*1 Table of Contents*
1.1 List of Tables
1.2 List of Figures
*2 Introduction*
2.1 Inferior Vena Cava Filters (IVCF) Overview
*3 Products under Development*
3.1 Inferior Vena Cava Filters (IVCF) - Pipeline Products by Stage of Development
3.2 Inferior Vena Cava Filters (IVCF) - Pipeline Products by Segment
3.3 Inferior Vena Cava Filters (IVCF) - Pipeline Products by Territory
3.4 Inferior Vena Cava Filters (IVCF) - Pipeline Products by Regulatory Path
3.5 Inferior Vena Cava Filters (IVCF) - Pipeline Products by Estimated Approval Date
3.6 Inferior Vena Cava Filters (IVCF) - Ongoing Clinical Trials
*4 Inferior Vena Cava Filters (IVCF) - Pipeline Products under Development by Companies*
4.1 Inferior Vena Cava Filters (IVCF) Companies - Pipeline Products by Stage of Development
4.2 Inferior Vena Cava Filters (IVCF) - Pipeline Products by Stage of Development
*5 Inferior Vena Cava Filters (IVCF) Companies and Product Overview*
5.1 Adient Medical Inc. Company Overview
5.1.1 Adient Medical Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.2 APT Medical Inc Company Overview
5.3 Contego Medical LLC Company Overview
5.4 CyndRX LLC Company Overview
5.5 Interventional & Surgical Innovations, LLC Company Overview
5.6 Kaleidoscope Company Overview
5.7 Koninklijke Philips NV Company Overview
5.8 Suzhou Tianhong Shengjie Medical Co Ltd Company Overview
5.9 University of Arizona Company Overview
5.10 University of Toledo Company Overview
5.11 Veniti Inc Company Overview
5.12 VueKlar Cardiovascular Ltd (Inactive) Company Overview
5.13 Zylox-Tonbridge Medical Technology Co Ltd Company Overview
*6 Inferior Vena Cava Filters (IVCF)- Recent Developments*
6.1 Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
6.2 Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
6.3 Sep 29, 2023: Barry Slowey Named Vice President and Chief Sustainability Officer
6.4 Sep 15, 2023: Amber Beauchamp Named Vice President of Global Human Resources
6.5 Aug 10, 2023: Vena Cava Filter System Saexten Approved by NMPA
6.6 Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility
6.7 Jun 04, 2023: Cook Medical receives additional 510(k) clearance for Gunther Tulip Vena Cava Filter Retrieval Set
*7 Appendix*
For more information about this report visit https://www.researchandmarkets.com/r/o042cg
*About ResearchAndMarkets.com*
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900